Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lol. Didn’t take long, did it?
In prior life I used CDARS strategy to spread out excess corp cash while insuring in FDIC increments. It’s what larger companies do. That would be a good problem to have.
I don’t believe shorting is the issue, but the price has been amputated since the last call that cannot he argued.
Thx. That makes sense if it’s for brand, but never heard of generics not being covered for Rx in adult space.
Any pharmacists running into insurance issues covering adult ADHD Rx? First I’ve heard of this.
“When I picked up my prescription, the pharmacist explained that a lot of insurers didn't want to cover adult ADHD prescriptions.”
https://reason.com/2024/04/23/it-took-me-months-to-get-the-adhd-meds-the-dea-says-are-overprescribed/
Agreed, regardless of what stock price dictates.
Small ones would at least put some life into the stock.
I think the accumulative 40% drop is also the nature of very to little volume and there have been a few decent size sellers since last call. Price has slowly drifted down with anticipation of no news driving new volume. Waiting for Q4 results is like the dead zone in the Gulf of Mexico.
Definitely agree on 2 small drugs not getting approved and PE ratio getting ridiculously low. Great buying opportunity for what is potentially in store.
It was the best sales Q, but didn’t live up to the hype CEO created. That was him putting his foot in his mouth yet again. Agree to disagree. Had they hit it out of the park with revenue last Q week wouldn’t be where we are today.
lol I’m sorry you sing praises to the CEO and worship him. He has made many mistakes in the past. I’m sorry you can’t see this. I could care less if I’m ignored.
It’s not worth that much today and we don’t have the best CEO, but he should be good enough to get the job done and lead us to a buyout if we can get the pending and upcoming anticipated drugs approved and launched successfully.
Q3 was not as big of a pickup from Prasco as CEO conveyed during Q2. I think the drop is whether Prasco is as big of a deal as anticipated. We’ll know in couple months.
Will rise in due time. Not any momentum after that last call. Initial Prasco shipment didn’t have expected financial benefit laid out in prior call. We’ll now have a full quarter of Prasco, but will it be as big as Nasrat hopes? TBD. Would be nice. Couple months still to go in the long stretch of no updates.
Yes, continued expected growth is exactly what I said. In the event happens that the company isn’t sold, you still want to plan longer term.
To position themselves for growth from operation perspective. Buyout valuation will be based on DCF including future growth accounting for any caped needs to continue the growth. Since we care nearing max storage capacity with current building it makes sense to both expand storage and mfg bandwidth to plan for near term growth.
Nothing would be expected here for several months, assuming no CRL.
Agree 100%. Was surprised to see this wording used from asst deputy at DEA. I think there are some similarities to opioid crisis, but drastically different in many ways too. I think 600K died from opioid crisis alone. Adderall pills bought online are perceived as Adderall, but may be fentanyl or other drugs. There is the perception of an Adderall crisis that I think Nasrat will want to navigate around and sell the company sooner rather than later as this can have a negative impact in risks for DCF analysis & buyout amount.
The fact that the stimulant issue is ongoing after many months and Vyvanse supply can’t be rectified is just really sad. Hoping this buys us time for Elite’s eventual approval in ‘24 or ‘25.
Perhaps in an ideal world. We’re still working on getting a couple small teeny drugs past CRLs. Realistically larger drugs won’t get approved in ‘24.
Agree 100% as we painfully await the dry spell until 10K release end of June. What is a bit frustrating is that we don’t even have news/approvals for the smaller drugs and are kept in the dark. Looking forward to seeing first full Q with Prasco partnership for Q4 to get a taste of the financial benefit.
Because he’s a lawyer and the optics of that are beyond reasonable. One can talk their way out of Mikah winding down as things can change, but not a buyout like this. Not even 1% chance of this happening. If Nasrat went this route it would be an onslaught of legal pursuits against his decision making. Plus, all shareholders would have to approve. He has a real nice share, but not the majority to sway such a crappy decision.
I only object to idiotic ideas. There are plenty here. Mikah only gets part of profit split. Majority of revenue is from mfg fees, which Elite gets.
No, Nasrat is chairman. That would look like a deal significantly in his favor with the pending filings with FDA. Not a chance even if premium at today’s prices.
There’s no way Mikah can buy out Elite.
How did that work out?
Doubtful. Elite is not going to get involved in a big drawn out lawsuit if they expect to be bought out in a couple years. They want to prop up that Balance Sheet and not waste it on egregious legal fees.
Not the first time. Someone did it couple months back. I rarely look at yahoo board anymore.
Clearly a fake. Very sad.
Correct. PR was due to the materiality expected. Nasrat mentioned that in a prior call. It’s not our news to share unless we expect a big financial impact to Elite.
Why would you add it to the buyout price when the contract would end around then and has no future cash flow benefit? Doesn’t sound like Nasrat’s is expecting the agreement to be extended. If things change, only then it would make sense to be included in forward looking DCF analyses for a buyout.
That’s the total market, not our market share.
Not our product to launch. We are only a contract mfr.
And with 4/1 launch there will be some mfg fee revenue to prep for small launch quantity sent to Pyros. This means revenue associated with the launch quantities will be included in Q4 financials.
Referring to “manufactured for” vs “manufactured by”?
Not sure what you are insinuating here, but any government funding or grants would be called out in financials similar to PPA in past. Nothing new there as of yet.
Looking forward to next cc with Q4 performance and expecting a forward looking update after few months of Prasco under our belt.
Are you really worried about the direction that $35K in total shareholder value made today? Who cares.
When has Elite ever parsed out only generic market in their PRs? I don’t think Methotrexate passed the bar to file. We filed a smaller antimetabolite.